DiaCarta, Inc.

DiaCarta, Inc.

DiaCarta, Inc.

Improving patient care through novel precision molecular diagnostics: CE/IVD marked tests are available for detection of KRAS, NRAS, EGFR, BRAF, PIK3CA, JAK2 .
Type
B2b
Founded
2010
Raised
$53M
Follow us
Alexa global traffic share
Latest funding
$45,000,000
Venture capital (Series B) - 2018
Fortune Fountain Capital Fortune Fountain Capital (FFC) Good Health Capital (GHC) +1
$8,000,000
Venture capital (Series A) - 2015
Team Size
10+
Employees
$45,000,000 Venture capital (Series B)
FinSMEs

DiaCarta Raises $45M in Series B Funding

Science Health